This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT) and Taysha Gene Therapies (TSHA)

Tipranks - Tipranks - Tue Jun 2, 6:52AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT) and Taysha Gene Therapies (TSHA).

Claim 55% Off TipRanks

Bristol-Myers Squibb (BMY)

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $66.00. The company’s shares closed last Friday at $57.18.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 9.9% and a 56.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $62.67, which is a 9.9% upside from current levels. In a report issued on May 19, Scotiabank also maintained a Hold rating on the stock with a $60.00 price target.

See the top stocks recommended by analysts >>

Corcept Therapeutics (CORT)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics, with a price target of $95.00. The company’s shares closed last Friday at $69.49, close to its 52-week high of $75.00.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 16.3% and a 44.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Janux Therapeutics Inc, and Unicycive Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corcept Therapeutics with a $97.50 average price target, implying a 42.2% upside from current levels. In a report issued on May 29, TipRanks – xAI also upgraded the stock to Buy with a $75.00 price target.

Taysha Gene Therapies (TSHA)

In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Taysha Gene Therapies, with a price target of $10.00. The company’s shares closed last Friday at $5.87.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.5% and a 53.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $12.67 average price target, representing an 113.7% upside. In a report issued on May 18, TipRanks – xAI also upgraded the stock to Buy with a $6.50 price target.

Read More on BMY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).